Generic medicine

Golimumab: Brands, Price & Uses in Bangladesh

Golimumab is a human monoclonal antibody (TNF-alpha inhibitor) approved for the following conditions: Moderate-to-severe active rheumatoid arthritis (RA) in adults and more.

Forms:SC Injection

About Golimumab

Indications of Golimumab

Golimumab is a human monoclonal antibody (TNF-alpha inhibitor) approved for the following conditions:

  • Moderate-to-severe active rheumatoid arthritis (RA) in adults, used in combination with methotrexate (FDA-approved, established use).
  • Active psoriatic arthritis (PsA) in adults, alone or in combination with methotrexate (FDA-approved, established use).
  • Active ankylosing spondylitis (AS) in adults (FDA-approved, established use).
  • Moderate-to-severe active ulcerative colitis (UC) in adults who have had an inadequate response to, or are intolerant of, conventional therapy (FDA-approved, established use).

The intravenous formulation of Golimumab is additionally approved, in some markets, for polyarticular juvenile idiopathic arthritis and pediatric psoriatic arthritis in patients 2 years of age and older (guideline/label-supported pediatric extension; see Use in Special Populations). Golimumab is not indicated for infectious or non-autoimmune forms of arthritis.

Dosage & Administration of Golimumab

IndicationRouteDose
Rheumatoid arthritis (with methotrexate)Subcutaneous50 mg once monthly, same date each month
Psoriatic arthritisSubcutaneous50 mg once monthly
Ankylosing spondylitisSubcutaneous50 mg once monthly
Ulcerative colitis - InductionSubcutaneous200 mg at Week 0, then 100 mg at Week 2
Ulcerative colitis - MaintenanceSubcutaneous100 mg every 4 weeks (50 mg every 4 weeks if body weight <80 kg, per treating physician's assessment)
RA / PsA / AS (intravenous formulation)Intravenous infusion2 mg/kg at Weeks 0 and 4, then every 8 weeks, infused over 30 minutes

All doses of Golimumab above 50 mg (subcutaneous, for patients weighing more than 100 kg) or as clinically indicated should be individualised by the treating physician. See Dosage, Administration, and Duration of Treatment sections for further detail.

Side Effects of Golimumab

Common (may affect more than 1 in 10-100 people):

  • Upper respiratory tract infection, nasopharyngitis
  • Injection-site reactions (erythema, itching, pain, swelling)
  • Mild elevations in liver enzymes
  • Hypertension

Serious (less common but clinically important):

  • Serious infections (bacterial, tuberculosis reactivation, invasive fungal, viral, other opportunistic infections)
  • Malignancies, including lymphoma (class warning for TNF inhibitors)
  • New-onset or worsening congestive heart failure
  • Demyelinating disorders (e.g., new-onset or exacerbated multiple sclerosis-like symptoms)
  • Serious hypersensitivity reactions, including anaphylaxis
  • Hepatotoxicity and cytopenias (rare)

See Precautions and Warnings for details on monitoring for these serious effects during treatment with Golimumab.

Contraindications of Golimumab

  • Known hypersensitivity to golimumab or any component of the Golimumab formulation.
  • Active, clinically serious infection, including sepsis and active tuberculosis.

See Precautions and Warnings for infection screening requirements (latent tuberculosis, hepatitis B) that must be completed before initiating Golimumab.

Frequently Asked Questions about Golimumab

What is Golimumab used for?

Golimumab is a biologic (TNF-alpha inhibitor) medicine used to treat moderate-to-severe rheumatoid arthritis (with methotrexate), active psoriatic arthritis, active ankylosing spondylitis, and moderate-to-severe ulcerative colitis in adults.

How is Golimumab given?

Golimumab is usually given as a subcutaneous injection once a month, or as an intravenous infusion at specified intervals administered by a healthcare professional. Do not change the dose or schedule without consulting your physician.

Who should not take Golimumab?

Golimumab should not be used in people with a known hypersensitivity to it, or in anyone with an active serious infection, including active tuberculosis or sepsis. You should be screened for latent tuberculosis and hepatitis B before starting treatment.

Is Golimumab safe during pregnancy or breastfeeding?

Golimumab should be used in pregnancy only if clearly needed, since it can cross the placenta, especially in the third trimester, and may affect the baby's immune system; live vaccines in exposed infants may need to be delayed. Use during breastfeeding should be discussed with your doctor, as data are limited but expected transfer into milk is minimal.

What are the most serious risks of Golimumab?

The most serious risks of Golimumab include serious infections (including reactivation of tuberculosis or hepatitis B), an increased risk of lymphoma and other cancers, new or worsening heart failure, and rare nervous-system demyelinating disorders. Report fever, persistent cough, unusual bruising/bleeding, or shortness of breath to your doctor promptly.

What should I do if I miss a dose or suspect an overdose of Golimumab?

If you miss a dose of Golimumab, take it as soon as you remember and resume your normal monthly schedule; do not double up. If an overdose is suspected, seek immediate medical attention or contact emergency services, as there is no specific antidote.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.

DoctorBlogArticles